Command Palette

Search for a command to run...

Concord Drugs Ltd.
68(+1.22%)
1W: +1.79%

Peers

Snapshot Summary

Concord Drugs Ltd. significantly underperforms in key financial metrics compared to its peers in the Pharmaceuticals & Drugs sector, showcasing low revenue growth, poor profitability, and high valuation ratios. It is a weak investment choice relative to its competitors, which display stronger fundamentals and growth trajectories.

  • • Concord Drugs Ltd. has negative revenue growth and the lowest ROE among peers.
  • • High PE ratio indicates overvaluation relative to earnings, alongside low margins.
  • • Strong competitors like Sun Pharmaceutical and Dr. Reddy's exhibit robust growth and profitability.
  • • Sun Pharmaceutical Industries Ltd.: Highest profitability with a strong ROE (16.13) and consistent revenue growth.
  • • Dr. Reddy's Laboratories Ltd.: Strong EPS growth and low PE ratio indicate excellent value with high profitability.
  • • Cipla Ltd.: Strong revenue growth and profitability metrics make it an attractive choice.
Stocks
CMP
Market Cap
P/E
ROCE (%)
Debt/Equity
Concord Drugs Ltd.₹62.96₹62.96Cr213.424.99%0.52
SUNPHARMA₹1,563.35₹3,75,099.26Cr87.5917.60%0.04
DIVISLAB₹6,091.05₹1,61,698.50Cr73.2016.46%-
CIPLA₹1,587.60₹1,28,217.27Cr23.7322.77%0.01
TORNTPHARM₹3,581.55₹1,21,215.77Cr61.5324.28%0.57
DRREDDY₹1,280.30₹1,06,835.27Cr15.5026.86%0.07
MANKIND₹2,518.95₹1,03,926.59Cr55.1828.38%0.02
Explore
Watchlists
Chat
Portfolio